<DOC>
	<DOCNO>NCT00582842</DOCNO>
	<brief_summary>The purpose study ass quality-of-life men prostate cancer . `` Quality-of-life '' mean feel life result disease treatment . The investigator hope questionnaire help show prostate cancer treatment affect quality-of-life . It help doctor future patient make good treatment choice . Some men may wish demand treatment high risk harmful effect . Others may prefer treatment small effect quality-of-life . This questionnaire help u measure effect decide best treatment give patient .</brief_summary>
	<brief_title>Longitudinal Assessment Health-Related Quality Life Men With Localized Prostate Cancer</brief_title>
	<detailed_description>The intent protocol ass health-related quality-of-life ( HRQOL ) men treat localized prostate cancer 1 6 establish management alternative : external ( XRT ) interstitial radiotherapy ( IRT ) , open radical prostatectomy ( RP ) , laparoscopic radical prostatectomy ( LRP ) , combine radiotherapy brachytherapy ( Combined RT ) watchful wait ( WW ) . HRQOL important aspect treatment prostate cancer due beliefs many cancer control rate similar across common modality HRQOL reduction treatment substantial ( 1-5 ) . Therefore , HRQOL appear occupy central role decision make process relate treatment selection .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>diagnosis localize , untreated prostate cancer ( clinical stage T13 , Nx , M0 ) ability read English language Exclusion criterion : cancer diagnosis past three year , except nonmelanoma skin cancer prior chemotherapy within last three year ; radiation therapy pelvis prior pelvic surgery within past three year prior neoadjuvant therapy , hormone ( Bicalutamide use less equal 1 month would constitute exclusion study entry ) For crosssectional component study , patient identify free disease least ten year post treatment consider eligible . Patients must clinical evidence local , regional distant recurrence . Patients must ability read understand English . Patients receive hormonal therapy eligible crosssectional component study , duration hormonal therapy must six month less . investigator identify cohort patient fit criterion database .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Early Stage</keyword>
	<keyword>Localized</keyword>
</DOC>